DE60043994D1 - Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung - Google Patents
Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendungInfo
- Publication number
- DE60043994D1 DE60043994D1 DE60043994T DE60043994T DE60043994D1 DE 60043994 D1 DE60043994 D1 DE 60043994D1 DE 60043994 T DE60043994 T DE 60043994T DE 60043994 T DE60043994 T DE 60043994T DE 60043994 D1 DE60043994 D1 DE 60043994D1
- Authority
- DE
- Germany
- Prior art keywords
- preparation
- interferon
- acid formulation
- stable acid
- interferon alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000003204 osmotic effect Effects 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB991255828A CN1175901C (zh) | 1999-12-06 | 1999-12-06 | 一种稳定的干扰素水溶液 |
| PCT/CN2000/000531 WO2001041793A1 (fr) | 1999-12-06 | 2000-12-05 | Formulation stable d'interferon en solution, son procede de preparation et ses applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60043994D1 true DE60043994D1 (de) | 2010-04-22 |
Family
ID=5284022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60043994T Expired - Lifetime DE60043994D1 (de) | 1999-12-06 | 2000-12-05 | Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20030170207A1 (de) |
| EP (1) | EP1250932B1 (de) |
| CN (1) | CN1175901C (de) |
| AT (1) | ATE460175T1 (de) |
| AU (1) | AU1848901A (de) |
| BR (1) | BR0016304A (de) |
| DE (1) | DE60043994D1 (de) |
| MX (1) | MXPA02005563A (de) |
| RU (1) | RU2242242C2 (de) |
| WO (1) | WO2001041793A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1245215C (zh) | 2001-02-28 | 2006-03-15 | 四川省生物工程研究中心 | 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂 |
| TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| US7585647B2 (en) | 2003-08-28 | 2009-09-08 | Guangwen Wei | Nucleic acid encoding recombinant interferon |
| AU2005244448B2 (en) | 2004-05-17 | 2011-03-17 | Ares Trading S.A. | Hydrogel interferon formulations |
| EA010979B1 (ru) | 2004-06-01 | 2008-12-30 | Арес Трейдинг С.А. | Стабилизированные жидкие препаративные формы интерферона |
| CN1724567B (zh) * | 2004-07-22 | 2010-08-18 | 北京三元基因工程有限公司 | 一种稳定的重组人干扰素α1b水溶液 |
| RU2255729C1 (ru) * | 2004-07-26 | 2005-07-10 | Общество С Ограниченной Ответственностью "Фармапарк" | Препарат интерферона альфа в форме стабильного водного раствора для инъекций |
| CU23432B6 (es) | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
| RU2319502C1 (ru) * | 2006-11-08 | 2008-03-20 | Общество С Ограниченной Ответственностью "Фармапарк" | РАСТВОР ДЛЯ ИНЪЕКЦИЙ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pSX50, КОДИРУЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО ЧЕЛОВЕЧЕСКОГО АЛЬФА-2b ИНТЕРФЕРОНА, ШТАММ Escherichia coli SX50 - ПРОМЫШЛЕННЫЙ ШТАММ-ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ЧЕЛОВЕЧЕСКОГО АЛЬФА-2b ИНТЕРФЕРОНА И СПОСОБ ПРОМЫШЛЕННОГО ПОЛУЧЕНИЯ ИНТЕРФЕРОНА АЛЬФА-2b |
| HRP20120483T1 (hr) | 2007-12-20 | 2012-07-31 | Merck@Serono@SA | Formulacije peg interferona beta |
| KR101303388B1 (ko) * | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| CN102988984B (zh) * | 2012-12-21 | 2015-05-20 | 嘉和生物药业有限公司 | 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂 |
| RU2564951C1 (ru) * | 2014-08-28 | 2015-10-10 | Закрытое акционерное общество "Вектор-Медика" (ЗАО "Вектор-Медика") | Композиция водного раствора рекомбинантного интерферона альфа-2 человека для ректального применения |
| CN106421755A (zh) * | 2016-11-03 | 2017-02-22 | 广州凯耀资产管理有限公司 | 一种干扰素组合物及其制备方法 |
| EP3970803A1 (de) * | 2020-09-22 | 2022-03-23 | Beiersdorf AG | Kosmetische zusammensetzung mit geringer osmolalität |
| RU2768656C1 (ru) * | 2021-09-10 | 2022-03-24 | Илья Александрович Марков | Противовирусное средство в жидкой форме и способ его приготовления |
| CN113797318B (zh) * | 2021-10-26 | 2023-06-30 | 深圳科兴药业有限公司 | 一种干扰素组合物及其制备方法和应用 |
| CN113797317B (zh) * | 2021-10-26 | 2024-01-09 | 科兴生物制药股份有限公司 | 一种组合物及其制备方法和应用 |
| CN115177719A (zh) * | 2022-07-29 | 2022-10-14 | 广州源博医药科技有限公司 | 一种犬α干扰素水针剂型及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0150067A3 (de) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stabile Gamma-Interferon-Zusammensetzung |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US6261800B1 (en) * | 1989-05-05 | 2001-07-17 | Genentech, Inc. | Luteinizing hormone/choriogonadotropin (LH/CG) receptor |
| CA2024046A1 (en) * | 1989-09-28 | 1991-03-29 | Alberto Ferro | Stabilized leukocyte-interferons |
| RU2095081C1 (ru) * | 1991-12-13 | 1997-11-10 | Акционерное общество "Биофа" | Фармацевтическая композиция антивирусного действия |
| US5482931A (en) * | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
-
1999
- 1999-12-06 CN CNB991255828A patent/CN1175901C/zh not_active Expired - Lifetime
-
2000
- 2000-12-05 BR BR0016304-0A patent/BR0016304A/pt not_active Application Discontinuation
- 2000-12-05 AT AT00981127T patent/ATE460175T1/de not_active IP Right Cessation
- 2000-12-05 US US10/148,865 patent/US20030170207A1/en not_active Abandoned
- 2000-12-05 EP EP00981127A patent/EP1250932B1/de not_active Expired - Lifetime
- 2000-12-05 WO PCT/CN2000/000531 patent/WO2001041793A1/zh not_active Ceased
- 2000-12-05 DE DE60043994T patent/DE60043994D1/de not_active Expired - Lifetime
- 2000-12-05 RU RU2002118115/15A patent/RU2242242C2/ru not_active IP Right Cessation
- 2000-12-05 AU AU18489/01A patent/AU1848901A/en not_active Abandoned
- 2000-12-05 MX MXPA02005563A patent/MXPA02005563A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP1250932A4 (de) | 2006-04-19 |
| AU1848901A (en) | 2001-06-18 |
| WO2001041793A1 (fr) | 2001-06-14 |
| MXPA02005563A (es) | 2004-09-10 |
| CN1175901C (zh) | 2004-11-17 |
| EP1250932B1 (de) | 2010-03-10 |
| EP1250932A1 (de) | 2002-10-23 |
| CN1256148A (zh) | 2000-06-14 |
| BR0016304A (pt) | 2002-11-05 |
| RU2002118115A (ru) | 2004-02-20 |
| ATE460175T1 (de) | 2010-03-15 |
| US20030170207A1 (en) | 2003-09-11 |
| RU2242242C2 (ru) | 2004-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60043994D1 (de) | Stabile wässrige formulierung von interferon, präparationsmethode und dessen verwendung | |
| DE60230160D1 (de) | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen | |
| IS4100A (is) | Aðferð við meðhöndlun á ígræðlingi úr málmi fyrirskurðaðgerð | |
| CY1110727T1 (el) | Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση | |
| DE69838986D1 (de) | Polypeptide, deren herstellung und verwendung | |
| DK0428642T3 (da) | Anvendelse af C-22 til C-26 alifatiske alkoholer til behandling af betændelses- og virussygdomme | |
| PT1146896E (pt) | Formulacoes monodispersas de analogo acilado e hexamerico insulina | |
| DE60137635D1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| ATE76569T1 (de) | Konservierte haar- und koerperreinigungsmittel sowie verwendung einer konservierungsstoffkombination. | |
| ATE132757T1 (de) | Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit | |
| ATE326947T1 (de) | Thixotropes nasenspray | |
| SE9300105D0 (sv) | Stable protein solution | |
| DK1146906T3 (da) | Mukosalt afgivelsessystem | |
| HUP9902415A2 (hu) | Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására | |
| ATE205399T1 (de) | Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält | |
| ATE395064T1 (de) | Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
| DE50111407D1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| IL148980A0 (en) | An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor | |
| ATE61522T1 (de) | Pharmazeutische zubereitung zur behandlung von tinea pedis. | |
| DK93091D0 (da) | Laegemidler til behandling af toxoplasmose | |
| NZ235297A (en) | Aqueous solution containing a protein and anionic polymer or salt and method of increasing the protein concentration of an aqueous solution | |
| ATE297720T1 (de) | Campher wässrige lösung zur behandlung degenerativer und autoimmuner erkrankungen sowie als immunomodulator | |
| FR2792639B1 (fr) | Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida | |
| ATE399551T1 (de) | Hilfsmittel und methoden zur transdermalen applikation von felodipin | |
| DE50000562D1 (de) | Mittel zur behandlung von pigmentierungsstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KNH PATENTANWAELTE KAHLHOEFER NEUMANN ROESSLER HEI |
|
| 8364 | No opposition during term of opposition |